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Celiac disease (CD) affects a growing number of individuals worldwide. To elucidate the
causes for this increase, future multidisciplinary collaboration is key to understanding
the interactions between immunoreactive components in gluten-containing cereals and
the human gastrointestinal tract and immune system and to devise strategies for CD
prevention and treatment beyond the gluten-free diet. During the last meetings, the
Working Group on Prolamin Analysis and Toxicity (Prolamin Working Group, PWG)
discussed recent progress in the field together with key stakeholders from celiac
disease societies, academia, industry and regulatory bodies. Based on the current state
of knowledge, this perspective from the PWG members provides recommendations
regarding clinical, analytical and legal aspects of CD. The selected key topics that require
future multidisciplinary collaborative efforts in the clinical field are to collect robust data
on the increasing prevalence of CD, to evaluate what is special about gluten-specific
T cells, to study their kinetics and transcriptomics and to put some attention to the
identification of the environmental agents that facilitate the breaking of tolerance to
gluten. In the field of gluten analysis, the key topics are the precise assessment of
gluten immunoreactive components in wheat, rye and barley to understand how these
are affected by genetic and environmental factors, the comparison of different methods
for compliance monitoring of gluten-free products and the development of improved
reference materials for gluten analysis.
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INTRODUCTION
About 60% of agricultural land worldwide is used to grow
cereals, with maize (1,135 × 106 metric tons), wheat (772 ×
106 metric tons) and paddy rice (770 × 106 metric tons) as
major crops in terms of global production (data from 2017,
FAOSTAT1). As an important source of dietary nutrients such
as carbohydrates, proteins, dietary fiber, vitamins and minerals,
wheat is an essential cornerstone for food security. However,
the consumption of products made of wheat, and the closely
related cereals rye and barley, may cause adverse reactions
such as celiac disease (CD), non-celiac gluten/wheat sensitivity
(NCGS) and wheat allergy. With increasing evidence from
epidemiological studies pointing to a large number of affected
individuals in many countries around the world, there is a
strong need to understand the fundamental interactions between
immunoreactive components in gluten-containing cereals and
the human gastrointestinal tract and immune system in order to
develop strategies for disease prevention and treatment beyond
the gluten-free diet (GFD). The term “gluten” includes the closely
related storage proteins of wheat (gliadins and glutenins), rye
(secalins), barley (hordeins), and oats (avenins). The part of
gluten soluble in aqueous alcohols has been termed prolamins
and the insoluble part glutelins.
CD is defined as a lifelong small intestinal immune
enteropathy with autoimmune features caused by ingestion of
gluten from wheat, rye and barley in subjects with a dominant
and necessary genetic predisposition [human leukocyte antigen
(HLA)-DQ2 or -DQ8] (1). The main known environmental
factor responsible for CD is the consumption of gluten, but
there still needs to be a largely unknown factor as initial
trigger of the disease. Certain viruses and bacteria are prime
suspects, and the idea is that virus infection can prime the
immune system in susceptible individuals so that not only the
virus is recognized and defeated but the intestinal immune
system also misinterprets gluten as “dangerous” (vide infra).
Patients develop characteristic mucosal (usually IgA) antibodies
to the autoantigen tissue transglutaminase [TG2, (2)]. TG2 can
deamidate gluten peptides, which improves their presentation by
HLA-DQ2 or -DQ8 on antigen-presenting cells of the intestinal
mucosa, and this increases their T-cell stimulatory potential (3,
4). While such gluten-specific T-cell responses are characteristic
for CD, it is unclear which events cause the loss of mucosal
tolerance to food antigens in CD. Many studies now imply a role
for additional environmental agents, including the exposure to
(intestinal) viruses and bacteria. CD is a systemic disorder that
predominantly manifests itself in the mucosa of the upper small
intestine (duodenum, proximal jejunum) and is characterized
by villous atrophy and crypt hyperplasia, which can vary from
mild partial damage to a total absence of villi. As a clinical
chameleon (5), CD presents in symptomatic, asymptomatic,
potential and refractory forms and can occur at any age. Notably,
CD often also presents with a wide variety of extra-intestinal
symptoms, including associated autoimmune diseases (6–9). The
1Food and Agriculture Organization of the United Nations (accessed December
11, 2019).
only effective treatment so far is a GFD that essentially relies on
the consumption of naturally gluten-free foods such as animal-
based products, fruits, vegetables, legumes and nuts as well as
dietary gluten-free products that may not contain more than
20 mg/kg of gluten according to Codex Alimentarius (Codex
Standard 118-19792). There are several ongoing attempts to
develop non-dietary treatments of the disease—this is briefly
discussed later.
Founded in 1985 by Professor Wim Hekkens, University
of Leiden, The Netherlands, the Working Group on Prolamin
Analysis and Toxicity (Prolamin Working Group, PWG)
coordinates multidisciplinary research efforts primarily related
to CD. The PWG currently has 13 executive members all of
whom are renowned experts in the fields of pediatric and adult
gastroenterology, immunology, biochemistry, plant science, food
chemistry, and gluten analysis. Building upon this unique
multidisciplinary knowledgebase, the PWG has made important
achievements both in clinical research into CD and in improving
food safety for CD patients by advancing analytical methods for
gluten detection.
Some of the highlighted clinical research work of the PWG
include the assessment of the safety of oats in the GFD (10–12),
the establishment of 10mg of gluten intake per day as the safe
gluten threshold for the vast majority of CD patients (13), the
search for wheat species with a reduced content of immunogenic
sequences for disease prevention (14, 15), and the study of the
signals for T- and B-cell recruitment into the lamina propria and
epithelial compartment (16).
Having been granted observer status at Codex Alimentarius
in 1999, the PWG plays a leading role in the development
of enzyme-linked immunosorbent assays (ELISA) for gluten
analysis (17) and the validation of such methods in collaboration
with the Cereals & Grains Association [formerly known as AACC
International; (18–20)], and AOAC International (21). It also
produced the only well-characterized reference material, the so-
called PWG-gliadin (22) that is used to calibrate a variety of
gluten analytical methods and is available in 100mg batches
from the Association of Cereal Research (Arbeitsgemeinschaft
Getreideforschung e.V., Detmold, Germany).
During its annual meetings, the PWG regularly unites a
select group of about 60 international stakeholders including
researchers, celiac disease societies, regulatory bodies,
manufacturers of gluten-free foods and raw materials, and
manufacturers of test systems for gluten analysis in foods. This
paper will report the recent progress and recommendations that
were presented and discussed during the last PWGmeetings.
UPDATE ON CLINICAL ASPECTS OF CD
The Epidemiology of CD
In several countries the epidemiology of CD has been intensively
investigated during these last decades (23, 24). In these studies,
the incidence of CD is calculated by counting the number of
new CD diagnoses in a population over a given period of time,
2Codex standard for foods for special dietary use for persons intolerant to gluten.
Codex Alimentarius Commission; revision 2008, amendment 2015.
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usually 1 year. On the other hand, the overall prevalence of CD
is determined through mass CD screening of general population
samples. The screening algorithm usually consists of serological
tests like IgA class anti-transglutaminase (TG2) antibodies. In
some of the studies, positive serology is backed up by gastroscopy
with duodenal biopsies for final confirmation of CD on an
individual basis. Taken together, these studies have shown that
there have been substantial increases in prevalence and incidence
over the last two decades (24).
Prevalence of CD on a Worldwide Basis
According to a recent meta-analysis, the pooled worldwide
prevalence of CD autoimmunity is 1.4% (95% confidence
interval, CI: 1.1–1.7%), based on positive results from tests
for IgA anti-TG2 and/or anti-endomysial antibodies (so-called
seroprevalence). This study found that the pooled global
prevalence of biopsy-confirmed CD is 0.7% (95% CI: 0.5–0.9%)
with wide regional variations. CD prevalence is 0.4% in South
America, 0.5% in Africa and North America, 0.6% in Asia, and
0.8% in Europe and Oceania; it is higher in female vs. male
individuals (0.6 vs. 0.4%; p < 0.001), and significantly greater
in children than adults (0.9 vs. 0.5%) (25). It should however
be noted that including only biopsy-confirmed CD cases tends
to underestimate the true CD prevalence (as it seems to be
the case for North America) since cases of potential CD (CD
serology positive with normal/nearly normal intestinal mucosa
at the small intestinal biopsy) are excluded from the prevalence
calculation. In some European countries, e.g., Sweden, Finland,
and Italy, data indeed show a significantly higher overall
CD prevalence (1.6–2.3%) (26, 27). Generally speaking, the
prevalence of CD is directly related to the population prevalence
of HLA-DQ2 or -DQ8 (30–40% in most Western countries) and
to the average level of wheat consumed per capita, as shown by
data from India: CD is much more common in the Northern part
of the country where wheat is the staple food (CD prevalence =
1.2), than in the Southern part with both a lower prevalence of
HLA-DQ2/DQ8 and a lower wheat consumption (CD prevalence
= 0.13%) (28).
The Concept of the Celiac Iceberg
CD screening studies have clearly shown that the percentage
of cases that are diagnosed clinically (the visible part of the
iceberg) is much smaller than the overall CD prevalence (the
submerged CD iceberg). The clinical severity of those detected
in regular clinical care and those detected by screening, does
not, however, seem to differ (29). In countries showing a high
level of awareness of the CD clinical spectrum, still 50–75%
of cases remain undiagnosed and are therefore exposed to the
risks of long-term complications. In some countries, such as
India and China, the visible CD iceberg is <5% of the overall
“mountain of ice.” How to increase the CD diagnostic rate (e.g.,
via mass-screening or case-finding) is still a matter of debate
(30, 31).
Is CD Prevalence Increasing Over Time?
Studies from several countries, particularly the US, Finland
and Italy, suggest that the overall CD prevalence is increasing
over time. For instance, the analysis of “old” sera samples
taken at two different time-points (15 years apart), coupled
with recent population screening data suggested that CD
prevalence increased 5-fold in the US during a 50-year
period beginning from 1948 to 1954 (32). The environmental
factor/s responsible for this huge increase are still unclear
(33). A recent study in Denmark showed that the prevalence
of diagnosed CD has doubled every decade from 1986 to
2016, the female/male ratio has increased, and also the
prevalence of autoimmune comorbidity in 2016 was three times
higher among CD patients compared with the general Danish
population (34).
Risk Factors
A number of prospective studies have been performed to identify
risk factors for CD. They were focused on the genetic factors
predisposing to the disease (in this context the dose of HLA-DQ2
seems to play the most important role) and on environmental
factors that increase the risk of developing celiac autoimmunity
and then mucosal damage.
Infant Feeding
Amongst those studies, two (PreventCD and CeliPrev) have
carried out an intervention based on the timing of gluten
introduction in infants. Other observational studies have assessed
the relationship between infant feeding practices and the risk
of CD (Generation R, Norwegian Mother and Child Cohort
Study, BabiDiab, TEDDY). In general, prospective studies have
not been able to confirm the previous findings that both age
of gluten introduction and breastfeeding influence CD risk (35,
36). Recent epidemiologic studies reported a positive correlation
between the incidence of CD cases and the amount of gluten
in the diet within the early years of life (37–39), but there
are also reports questioning this relationship (40–42). Further
immunological and multicentre studies are mandatory to assess
whether a reduced gluten exposure in early life may protect from
CD onset in predisposed individuals.
Early Events
A large registry-based cohort study that included over 1.5 million
children from Denmark and Norway found no association
between the mode of delivery (cesarean section vs. vaginal birth)
and the risk of diagnosed CD (43). Data collected from the
same cohort indicated that exposure to systemic antibiotics in
the first year of life was positively associated with diagnosed CD,
with a dose-dependent relation between an increasing number
of dispensed antibiotics and CD risk (44). However, a recent
systematic review of two studies on prenatal and three studies
on postnatal antibiotic exposure reported contradictory results
and thus rather excluded an association between antibiotic use
and the risk of developing CD (45), as already suggested by the
TEDDY study (46).
Infections
Longitudinal prospective studies have suggested an association
between frequent rotavirus infection and an increased risk of CD
(47). A protective effect of rotavirus vaccination has also been
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reported (48). Both reovirus and norovirus (49) have been shown
to be able to break oral tolerance in murine models and there
is evidence for the role of reovirus in the pathogenesis of CD
(50). In addition, infections with enterovirus A and B, especially
with high titer and long duration, during early childhood were
associated with later CD, whereas adenovirus infections were
unlikely to contribute to CD onset (51). Interestingly, also
the occurrence of acute respiratory infections seems to play a
role (52).
Microbiota
Microbiota has been hypothesized to influence the risk of
developing CD. Studies on active CD patients have suggested
that microbiota from CD patients may harbor more pathogenic
or proinflammatory bacteria (53, 54). However, in such studies
on active CD patients, it cannot be stated whether dysbiosis
is a risk factor for CD or a consequence of mucosal damage
and inflammation. In infants carrying the high risk genotype
a reduced number of Bifidobacterium (B. longus) was found.
Early alterations of the proportions of Firmicutes were noted
in children who later progressed to CD (55). However, in
another study no statistically significant differences in the
fecal microbiota composition were found between children
who later developed CD and the control children without
disease or associated autoantibodies (56). Mouse experimental
studies, including fecal transplants from patients, demonstrated
a protective effect of certain lactobacilli that are able to
degrade immunogenic gluten peptides, thus alleviating small
intestinal damage (57). Microbe-host interactions were recently
identified as relevant factors in the development of food
sensitivities. Duodenal biopsies from CD patients displayed
increased proteolytic activity due to higher abundance of
Proteobacteria that express gluten-degrading enzymes such as
elastase (LasB). This resulted in the activation of an elastase-
dependent, but gluten-independent inflammatory response
mediated by the protease-activated receptor 2 pathway. In
the presence of CD risk genes, a synergistic effect between
elastase and gluten was demonstrated, thus highlighting the
importance of microbiota in modulating the host immune
response (58).
Natural History
The natural history of CD proceeds based on the prominent
genetic risk (HLA-DQ2/DQ8) and exposure to environmental
risk factors finally to break the oral tolerance to gluten. The
seroconversion with the appearance of anti-TG2 autoantibodies
(CD autoimmunity) is considered to be a sign of activation
of anti-gluten adaptive immunity, being sustained by gluten-
specific T cells. However, not all subjects in this stage
appear to progress further to villous atrophy and consequent
malabsorption (59). Some may remain at this stage with no
histological damage or very mild lesions. This condition has been
dubbed “potential CD.” In a subset, anti-TG2 antibodies may
fluctuate or even disappear (60, 61). Recently, factors predicting
such evolution have been suggested, such as increased density
of intraepithelial γδ T cells, small intestinal mucosal deposits of
anti-TG2 antibodies, and HLA dose (62).
Clinical Gluten Challenge and the Adaptive
Response to Gluten
For decades, the roles of the adaptive and the innate immune
system as the key players in CD immunopathogenesis have been
discussed. The very clear genetic association primarily to HLA-
DQ2.5 and to a lesser degree to HLA-DQ2.2 and HLA-DQ8,
and the finding that these HLA molecules present gluten to
lamina propria CD4+ T cells all argue for a prominent role
of the adaptive immune system (63–66). In addition, there
is a very strong HLA-DQ2 gene dose effect which correlates
with stronger gluten-specific T-cell responses in individuals
homozygous for HLA-DQ2.5 compared to heterozygotes (67).
Very recent studies demonstrated that the DQ2.5 genes are more
expressed than non-CD associated alleles in antigen-presenting
cells heterozygous for DQ2.5. This differential expression of CD
risk genes affects the level of the encoded DQ2.5 molecules on
the cell surface and the strength of gluten-specific CD4+ T-cell
response (68–70). According to these findings, the magnitude
of the T-cell response appears more prominent dependent on
the amount of gluten and less on the DQ2.5 gene doses.
Although innate effects of gluten also may be important, these
are generally only found in patients with CD and not in healthy
individuals. Lamina propria CD4+ T cells recognize certain
peptides from the gluten protein types α/β-, γ-, ω-gliadins, and
high-molecular-weight glutenin subunits (HMW-GS) where the
common denominator of this peptide recognition is that the
peptides are deamidated by the enzyme TG2 (2, 3, 71, 72),
although some sequences do not need deamidation to be CD-
active. The set of peptides presented by any given of the two
CD-associated HLA molecules share common features where
the charged amino acids of the gluten peptides fit into pockets
of HLA-DQ2/DQ8 molecules (9, 73–75). The CD4+ T cells
preferentially recognize these, partly deamidated peptides that
cluster in proline- and glutamine-rich stretches of the gluten
proteins. However, the peptide sequence of only ≈50% of the
total number of such lamina propria T cells can be accounted for.
Although often termed an “autoimmune” disease, this is mainly
related to the production of autoantibodies to TG2, as hallmark
of CD, while T cells recognizing TG2 do not appear to play
a role.
The gluten-specific T cells can be demonstrated by in vitro
culture of biopsies from CD patients, as first shown in the early
1990’s (64, 65). They can also be demonstrated by direct staining
using so-called HLA-DQ:gluten peptide tetramers; i.e., tetramers
of HLA-DQ molecules with gluten peptides bound (76). It was
shown that a short gluten challenge will mobilize gluten-specific
T cells into the peripheral blood (77, 78), and such cells can be
quantified by ELISpot or by HLA-DQ:gluten tetramers (79). Such
T cells express markers for gut-homing, but if they actually are
mobilized from the intestine remains uncertain. The procedure
can be used for diagnostic purposes after gluten challenge
(80) and may perform better than a 2-week gluten challenge
followed by upper endoscopy with biopsy (81). Furthermore,
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employing an improved methodology, such HLA-DQ:gluten
tetramer+ cells can be detected without gluten challenge and
clearly distinguish CD patients and healthy individuals (82,
83). When the HLA tetramer technology was coupled with
the CyTof technology, it was found that these cells carry a
surprisingly rare phenotype with a profile suggesting that they
may help plasma cells. Importantly, they are similar in profile
to disease-relevant T cells in other autoimmune diseases, where
the antigen specificity is unknown (84). Most recently, Zühlke
et al. have demonstrated that the HLA-DQ:gluten tetramer+
cells after gluten challenge show interesting features: (1) the
kinetics of appearance peaks between day six and eight, (2)
there are large inter-individual differences in numbers of cells,
(3) even a one-day, single challenge with gluten mobilizes
detectable cells, (4) although the numbers of cells vary between
individuals, expression of the activation marker CD38 on the
HLA-DQ:gluten tetramer+ cells is a very specific and sensitive
parameter (85). Thus, the HLA-DQ:gluten tetramers may be
developed as a powerful diagnostic tool for CD but are not yet
available outside the research setting and are not approved by any
guidelines (86).
The importance of the adaptive immune system has recently
been strongly supported by finding of the bona fide T cell
cytokine IL-2 as fast as 4 h after ingestion of gluten. This was
first shown after intradermal injection of gluten peptides but
the same is seen after peroral gluten exposure (87). No such
response is seen after gluten intake by non-celiac, gluten-free
subjects (88). It is conceivable that either the HLA-DQ:gluten
tetramers or the IL-2 response can be used as surrogate
markers for testing of therapies for CD; this is the focus of
ongoing research.
Compliance With the Gluten-Free Diet
Although a strict GFD remains the only effective treatment for
CD, the rate of compliance is far from 100%. Adherence to
the diet is higher in children and, in general, in those who
have received diagnosis in early childhood (89). Socioeconomic
factors, sex, access to health care facilities also influence the
level of compliance. Adherence to the GFD is not easy to
assess, clinical improvement not being a valid criterion. Periodic
interviews conducted by dieticians could monitor compliance,
with structured short, validated, dietary questionnaires being
an alternative to consultations with a dietician (90). Anti-
TG2 serology is in clinical practice the most used current
method. In fact, antibody titers decrease after a few weeks on
a strict GFD, but sometimes it can take longer, particularly
if high titers are present at diagnosis. In any case antibody
measurement cannot reveal minor dietary transgressions (91).
The best way remains performing duodenal biopsies, but this
is invasive and should be reserved to cases with no clinical
improvement or no decrease of serological titers. More recently
detection of gluten immunogenic peptides (GIP) in feces and
urine has been proposed as new biomarker to detect gluten
intake and verify GFD compliance in CD patients. Their
determination is non-invasive and relatively simple, but shows
poor correlation with antibody levels or with the response to
dietary questionnaires (92).
UPDATE ON GLUTEN DIGESTIBILITY AND
DEVELOPMENT OF NON-DIETARY
TREATMENT
Gluten Digestibility Influences Its
Stimulatory Properties
Gluten, the trigger factor of CD, is composed of hundreds of
monomeric, oligomeric, and polymeric proteins, these latter
interlinked by disulfide bonds (93). The unique amino acid
composition of gluten proteins, enriched in glutamine and
proline residues, makes this important dietary component
highly resistant to gastrointestinal digestion (94). The inability
of gastric and pancreatic proteases, as well as of the brush
border membrane endopeptidases, to cleave proline-glutamine
bonds throughout the gluten protein sequences leads to peptide
fragments of different lengths that escape proteolytic degradation
(95). These gluten peptides retain a marked immunogenic
potential, as they pass across the small intestinal epithelial barrier
and may trigger an adverse immune response in genetically
susceptible individuals (96). It has been demonstrated that in
patients with CD some long gluten peptides are site-specifically
deamidated by TG2, bound to HLA class II molecules of antigen-
presenting cells, and stimulate a specific immune response
mediated by CD4+ T cells. These mucosal T cells proliferate and
release several inflammatory cytokines, such as interferon-γ and
interleukin-21 with a key role in activating the injurious process
of villous atrophy (97). Recently, the nomenclature of the existing
CD-relevant gluten epitopes recognized by CD4+ T cells has been
updated (98). However, it has to be emphasized that the pool of
CD-active sequences is far from being complete to date as the
epitopes recognized by many T cells are not known. The clinical
importance of these sequences is, however, uncertain.
A “new” class of poorly digestible proteins in wheat, the
amylase/trypsin-inhibitors (ATI), has received a lot of attention
recently, but their potential role in the pathogenesis of CD needs
further investigation (99–101).
Gluten Degradation as a Treatment
The current therapy for CD patients is the lifelong withdrawal
of gluten from the diet. Although, the GFD is efficacious in
the great majority of patients, with the restoration of mucosa
villous morphology and function, many young patients are
poorly compliant, so that the identification of an alternative
treatment would be beneficial for those patients for whom the
GFD fails or is impracticable (102). Recently, great efforts were
made to identify a pharmacological therapy that could be used
to replace or support the GFD for treatment of CD patients
(103). Currently, several proteolytic enzymes of microbial or
plant origins have demonstrated a high efficiency to quickly
degrade gluten proteins at very low pH, as occurring in gastric
conditions (104–107). These glutenases, thanks to their efficacy
in cleaving the proline- and glutamine-rich gluten sequences
are promising drugs to abolish the immunogenic potential of
dietary gluten. Both in vitro and pre-clinical studies have shown
that the glutenase treatment results in a marked reduction of
the amount of gluten epitopes in wheat-containing food. The
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possibility of preventing that gluten immunogenic peptides reach
the duodenal mucosa strongly suggests the possible use of
glutenases in oral enzymatic treatment for CD (108). AN-PEP,
a prolyl endopeptidase from Aspergillus niger, even though it
was not intended to replace a GFD, was effective as a digestive
aid protecting against the unintentional intake of gluten (109),
or when consuming food which may contain small amounts
of gluten, e.g., beer. A recent study demonstrated that the
endopeptidase E40 from Actinoallomurus A8 is a fast-acting and
strongly efficient glutenase, and thus a candidate as enzyme
adjuvant to a GFD for the dietary management of CD (104).
Glutenases can also be induced in wheat by germination but
the activity is not high enough to be useful as an oral food
supplement. However, this strategy can, for example, be used
to eliminate residual gluten from food such as beer (110).
Special wheat lines were developed recently to express the barley
endoprotease B2 combined with a prolyl endopeptidase from
Flavobacterium meningosepticum or Pyrococcus furiosus that
significantly reduced the amount of indigestible gluten peptides
(111). Sequence guided site-saturation mutagenesis was used to
enhance the thermostability of these enzymes and allow their use
in heat-treated cereal products (112).
Development of Other Non-dietary
Treatment Options
As repeatedly stated in this paper, the GFD is a well-established
and effective treatment for CD, at least as long as the patient is
fully compliant. Here it is also important to emphasize that a
GFD is inherently associated with nutritional deficiencies and not
recommended except in the treatment of gluten-related disorders
(113). It may be noted that no randomized, controlled trials have
been performed to prove the real effects of the treatment, but
this is not unusual in medicine. CD patients themselves express
huge interest in non-dietary treatments like drugs or vaccines
(114). Attractive options include sequestering of gluten within
the lumen, luminal digestion of gluten by exogenous enzymes,
interfering with mucosal integrity (tight junctions), inhibition of
TG2, inhibition of antigen presentation, immune skewing and re-
establishment of oral tolerance or clonal deletion, to mention a
few (115–119). A plethora of Phase 1 studies, a small handful of
Phase 2 and a single Phase 3 study is ongoing at the moment, but
no drugs have reached the market. Almost all of these studies are
based on preclinical studies in vitro and ex vivo. This research
is hampered by the lack of good line research opportunity as
the immune reaction to gluten is dependent on intact mucosal
interaction. It is also hampered by lack of good animal (mouse)
models for CD, although there are several mouse models for
immune reaction to gluten (120, 121). Recently, a mouse model
was developed that reproduces the overexpression of interleukin-
15 (IL-15) in the gut epithelium and lamina propria, expresses the
predisposing HLA-DQ8 molecule, and develops villous atrophy
after ingestion of gluten (122). At any rate, it can be foreseen that
such non-dietary options will come to the market, either as add-
on therapy to the GFD, as rescue therapy after incidental gluten
exposure or as replacement of the GFD.
UPDATE ON GLUTEN COMPOSITION OF
WHEAT AND METHODS FOR
MODIFICATION
Gluten Content and Composition in Wheat
Species and Cultivars
The availability of the first annotated reference sequence for
the hexaploid bread wheat genome containing 107,891 high-
confidence gene models (123) recently allowed the establishment
of a genome reference map for immunostimulatory wheat
proteins (124). One of the hypotheses being discussed to explain
the increasing prevalence of CD is that the protein composition
of wheat may have changed over the past decades due to breeding
and agronomic practices. The main goals of wheat breeding
are increased yield, improved resistance against plant diseases,
pests, and climatic stress, more efficient use of fertilizers as well
as increased protein content. The protein content represents
one of the key quality aspects that significantly influences the
bread wheat quotation worldwide. With CD being determined
by gluten as major and necessary environmental risk factor and
HLA-DQ2/DQ8 as genetic risk factors, one might envisage to
be able to predict the prevalence of CD in different countries. A
systematic worldwide compilation of this data revealed that those
two factors are clearly required for the development of CD, but
not suitable to predict the prevalence. There was no correlation
between CD prevalence, the levels of wheat consumption and
the frequencies of HLA-DQ2/DQ8 or the combination of both.
This rather surprising result was primarily due to several outlier
populations in regions such as north-western India, northern
Africa, Mexico, Finland, and Russia. For example, the prevalence
of CD in Finland is among the highest worldwide (2.4%), whereas
that of neighboring Karelia (Russia) is very low (0.2%), although
both regions share similar levels of wheat consumption and
frequencies of HLA-DQ2/8 (125). Within the United States, CD
was 5.4-fold more common among individuals who lived at
latitudes of 40◦ North or more than among individuals who
lived at latitudes below 35◦ North, independent of race or
ethnicity, socioeconomic status, and body mass index (126). This
discrepancy can only be explained by further environmental
factors that cause a loss of tolerance to dietary gluten and
initiate CD (23, 24). Although there was no clear trend toward
higher protein or gluten contents since the 1950s (127), the
selection criteria for breeding might have resulted in a higher
immunostimulatory potential of wheat (128). Several studies
have explored the protein composition of different wheat species
and cultivars of hexaploid bread wheat (Triticum aestivum subsp.
aestivum) and spelt (T. aestivum subsp. spelta), tetraploid durum
wheat (T. turgidum subsp. durum), and emmer (T. turgidum
subsp. dicoccum) as well as diploid einkorn (T. monococcum)
with respect to their content of potentially immunostimulatory
proteins (15, 129–131).
There is evidence for changes in gluten protein composition
(132–134) with decreasing contents of gliadins and total gluten,
but increasing contents of glutenins from diploid to tetraploid
and hexaploid wheats. However, within bread wheat or durum
wheat, there were no clear differences in the contents of selected
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CD-active epitopes between modern cultivars and landraces not
subjected to breeding (135–138). All studies consistently reported
a significant effect of environmental conditions on the expression
of CD-immunogenic peptides, with e.g., low or high cultivation
temperatures affecting the expression of immunostimulatory
proteins in different ways (124). This high variability in protein
composition regulated by mechanisms in the wheat plant that are
still incompletely understood complicates the search for specific
cultivars that naturally express low amounts of CD-immunogenic
peptides independent of the environmental conditions.
Recent studies have shown that gluten proteins of several
einkorn (T. monococcum) landraces have a reduced capability
of activating the mucosal innate immune cells and inducing
enterocyte apoptosis (14). Other studies have attributed the
reduced immunotoxicity to the presence of protective sequences
(139). A recent study demonstrated that wheat gluten from
einkorn is extensively degraded by the gastrointestinal protease
cocktail, including endopeptidases of the villous brush border
membrane (15). This results in the release of a reduced amount
of peptides that can activate pathogenic CD4+ T cells in the
gut mucosa. Altogether, these findings are relevant from the
perspective of disease prevention, taking into account that the
incidence of CD is much higher (≈10%) in first-degree relatives
of CD patients carrying the high-risk HLA-DQ genes (36).
However, the evidence cited in support of T. monococcum is still
insufficient, and it is not recommended to include this wheat
species into the diet of CD patients.
Removing Gluten From Wheat
It is likely, that no existing wheat species or variety is completely
safe for use by CD patients, as they all contain far more than
20 mg/kg of gluten. Can we specifically develop wheat varieties
that are CD-safe? In barley, an ultra-low gluten variety has
been developed that is safe for CD patients, as it contains <20
mg/kg of gluten. It was developed by combining existing induced
recessive mutations through breeding (140). This strategy is very
difficult to implement in bread wheat as it has three genomes
and one does not want to remove all gluten genes (141), but
other approaches may be successful (142, 143). The general
applicability of these breeding approaches needs to be discussed,
since only gluten endows the dough with the desired properties
for bread making.
Using RNA interference (RNAi), several groups have shown
that it is possible to strongly reduce the expression of α-gliadins
(144), γ-gliadins (145), ω-gliadins (146, 147), or all of them
(148) in wheat. In the latter study, the α- and ω-gliadins were
downregulated to the extent that no CD epitopes could be
detected using LC-MS/MS (148). Unfortunately, these lines are
genetically modified (GM) as the RNAi construct must remain
present. As no GM wheat has been commercially introduced
anywhere in the world, it is unlikely that these lines will reach
the market shortly.
A recent alternative technology is to use gene editing with
CRISPR/Cas9 to delete gliadin genes in order to produce gluten-
free wheat and/or to edit the epitopes in them to generate wheat
with safe gluten. Sánchez-León et al. (149) targeted two conserved
sites adjacent to the epitope-containing region in the α-gliadin
genes. Up to 35 of the 45 α-gliadin genes were mutated in a
single line, with small or larger deletions around the target sites.
This line showed a 85% reduction of the R5 and G12 ELISA
signals. Jouanin et al. (150) simultaneously edited multiple sites
in α- and γ-gliadins with a single construct. Although the lines
produced in these pilot studies are not yet safe, they demonstrate
the power of gene editing for effectively modifying tens of genes
of multiple gene families in a polyploid species at once. The Cas9
construct used to generate the edits is removed afterwards by
crossing, leaving only mutations that are identical to what can
occur naturally. In most of the world, the resulting plants are not
considered as GM, with the exception of the EU (151).
UPDATE ON THE USE OF ELISA FOR
GLUTEN ANALYSIS
Advances in Compliance Monitoring of
Gluten-Free Products
Apart from evolving proteomics-based detection methods,
enzyme-linked immunosorbent assays (ELISAs) are most
commonly used to monitor the compliance of gluten-free
products to the regulatory threshold of 20 mg/kg of gluten
(Codex Standard 118-19792). There are more than 20 ELISA
test kits on the market that use different principles (sandwich
vs. competitive), extraction procedures, reference materials for
calibration and various polyclonal or monoclonal antibodies
such as the Skerritt (401.21) (152), R5 (153), G12 (154), and
α20 (155). A wide variation in the reported measurement
results between different commercial kits were observed in
several studies (156–158). These discrepancies were mainly
attributed to the use of different reference materials and to
the fact that the used antibodies target only a fraction of
gluten components whose proportions may vary according
to the contamination source. The ELISA R5 Mendez Method
is currently laid down as a Codex type I method for gluten
determination in foods and, therefore, continues to be the
most widely used assay. However, the R5 ELISA has two
disadvantages; first it overestimates gluten from rye and barley
when calibrated to gliadins and secondly, it does not detect
glutelins adequately and the gluten content is calculated by
multiplying the prolamin content detected by a factor of two.
To address these limitations, a new sandwich ELISA based on
four different monoclonal antibodies was developed that detects
prolamins from wheat, rye and barley as well as HMW-GS,
HMW-secalins from rye and low-molecular-weight (LMW)-GS
from wheat. The performance of the test kit was recently
validated for the quantitative analysis of wheat, rye and barley
gluten in oat and oat products by an international collaborative
study with 19 laboratories. The results of the study showed
recoveries ranging from 99 to 137% for wheat, rye and barley
when analyzing defined validation materials (159, 160) and
relative reproducibility standard deviations from 10 to 53% for
samples containing 10 mg/kg of gluten or higher. Following
review by the AOAC Expert Review Panel for Gluten Assays,
the method was adopted as AOAC Official Method First Action
2018.15 (21).
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A Five Cultivar Wheat Blend Is Suitable for
New Reference Material Production
Reference materials that are representative of the target analyte
are essential prerequisites for calibrating and assuring the
accuracy of analytical methods. They form the basis for method
establishment and validation, proficiency tests, and verification
of the comparability between different methods and laboratories
(161–163). The use of appropriate reference materials was
recently shown to efficiently reduce the disparity of gluten
analysis between different commercial kits (157). A variety of
different reference materials are used in ELISA test kits for
gluten analysis including wheat or gluten preparations, some
of which are proprietary to the respective kit manufacturer
with little information on their exact composition related to
immunoreactive sequences. Food matrix and food processing are
also known to influence analytical results, which is why incurred
materials are recommended to reflect the properties of actual
food samples as closely as possible.
The best characterized reference material available for gluten
analysis is the so-called PWG-gliadin that was developed by our
group of experts. PWG-gliadin constitutes the purified gliadin
fraction extracted from a mixture of the 28 most common
European wheat cultivars, as of 1999 (22). It is homogeneous,
completely soluble in 60% ethanol, representative for European
wheat, regularly monitored for stability and widely used to
calibrate ELISA test kits and other methods for gluten analysis
(164, 165). However, as its supply is limited, efforts to develop
new reference and incurred materials are currently underway.
A collection of wheat cultivars from different countries was
characterized for gluten protein composition and ELISA
response to establish selection criteria and identify cultivars that
are as representative as possible for the multitude of cultivars
grown worldwide. A blend of the selected five cultivars from
Asia (Yumai-34), Australia (Yitpi), Europe (Akteur, MvMagvas),
and North America (Carberry) was further characterized and
appears to be suitable for further reference material development
(166, 167).
CODEX ALIMENTARIUS AND GLUTEN
QUANTITATION BY ELISA
Codex analytical methods are being revised every 10 years
and revision of the R5 Mendez ELISA was due in 2018.
Thus, it is time to discuss how to handle ELISAs for gluten
quantitation regarding approval by the Codex Alimentarius.
Based on the matrices used for validation, the R5 method has
been recommended for gluten quantitation inmaizematrices and
the G12 method for the analysis of rice matrices. Both methods
fulfill the performance requirements for gluten analysis set by
the Codex Standard 118-19792, i.e., a limit of quantitation of
10mg gluten/kg or less and the detection of CD-active epitopes.
The recently developed Total Gluten ELISA covers both gluten
fractions and, thus, measures the gluten content (21). This is an
important step forward compared to the R5 and G12 ELISAs that
measure the prolamin content and this is then converted into the
gluten content by multiplication with the factor of two.
Concerns
A major concern, in particular of celiac societies, CD patients,
food producers, and national food control laboratories is
the unclear situation, if several ELISA methods for gluten
quantitation were endorsed. It can be assumed that each
analytical laboratory would use one ELISA as the default method
for gluten quantitation. Consequently, it would be unclear, if
a value obtained by one laboratory with one kit would be
comparable to the value provided by a different laboratory with a
different kit. This would lead to the question of how to handle
conflicting results from different laboratories. In general, the
possibility of having two type I methods has to be questioned,
because the definition of a type I method as “the only method”
should exclude approval of a second type I method. On the other
hand, if a proprietary method fulfilling the performance criteria
of the Codex is on the market and has been approved by suitable
collaborative studies, it should not be excluded due to the fact
that another method has already been endorsed by the Codex
Alimentarius. Both the R5 and G12 sandwich ELISAs have been
compared in a number of scientific studies. In summary, the
results of these studies strongly suggest that these methods do not
yield comparable results. Typical examples are papers published
by Bugyi et al. (156), Bruins Slot et al. (168), and Scherf (158).
Position of the PWG
Therefore, the PWG suggests that ELISA methods should be
approved using a combination of
(1) information on the method that has been used to provide the
analytical value,
(2) strict performance criteria and
(3) a pre-defined set of maximum five matrices.
This would be similar to the Standard Method Performance
Requirements (SMPR) published by AOAC International for
allergen-containing commodities such as whole egg, milk,
peanut, and hazelnut (169).
Performance Criteria
Performance criteria include the correct setup and statistical
evaluation of validation studies (161, 170, 171) as well as the
fulfillment of the requirements for standardmethod performance
(172). The minimal performance requirements set in AOAC
SMPR 2016.002 (169) for whole egg, milk, peanut and hazelnut
can be adapted to gluten. Possible performance criteria are
summarized in Table 1. AOAC suggests low recovery rates of
60%, but the PWG feels that, in general, the recovery range
should be between 80 and 120%, which is in line with Abbott et al.
(161). With respect to LOD and LOQ, the three ELISAs under
consideration perform well and meet the requirements (18–21).
Matrices
Matrices should not be based on botanical origin (e.g., rice-
or maize-based), but on constituents that most likely affect the
interaction of the antibodies with the gluten antigens. Possible
matrices should be categorized into protein-based, starch-based,
fat-based, polyphenol-rich, and fiber-rich foods (173). Table 2
suggests categories and examples for foods from each category.
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TABLE 1 | Method performance requirements for gluten ELISAs.
Parameter Value/Range
Analytical range (mg/kg) 5–100
Limit of detection (LOD) (mg/kg) 3
Limit of quantitation (LOQ) (mg/kg) 10
Recovery (%) 80–120
Repeatability relative standard deviation (RSDr) (%) 20
Reproducibility relative standard deviation (RSDR) (%) 30
TABLE 2 | Suggested matrix categories and examples for foods from each
category.
Category Examples
Protein-based Coated meat, sausage, protein isolate/concentrate
Starch-based Starch, baked goods, sauce
Fat-based Cookie, cake, ice cream
Polyphenol-rich Chocolate cake, cocoa powder, beer
Fiber-rich Cereal bran, breakfast cereals, legume seed flours
Examples are limited to three per category to keep the number
of required analyses in validation studies in a range that can
be handled. Kit manufacturers are encouraged to agree on a set
of matrices which should be comparatively analyzed using their
methods. In case of conflicting R5/G12 results, in particular in
the concentration range of the 20 mg/kg threshold, the higher
concentration value should be considered relevant in the interest
of the celiac consumers. In future analyses, it should then be
avoided having to do two ELISAs. For any analysis value, the




Clinical Aspects of CD
Based on the most recent findings regarding epidemiological and
clinical aspects of CD as discussed above, the PWG recommends
the following priority research areas. With the recognition of
CD just beginning to emerge, particularly in sub-Saharan Africa
and Eastern Asia, more data needs to be collected in order to
make a robust estimate of the prevalence of CD in these parts
of the world. Recent epidemiological findings from Denmark,
Finland, Italy and the US suggest an increasing prevalence of
CD over time, but the reasons for this still remain unknown.
Among the factors being suggested are genetic and epigenetic
as well as environmental factors of which infectious agents
are most likely to play a role. In order to assess the specific
contributions of these factors toward increasing the risk of CD
development, the natural history of the disease needs to be
understood in more detail. Currently, there are still gaps in our
knowledge on how the disease proceeds from the genetic risk
combined with exposure to environmental risk factors in the
initial loss of oral tolerance to gluten. Even then, some individuals
remain at this stage of activated anti-gluten adaptive immunity
with no or very mild histological abnormalities, whereas others
progress to full-blown villous atrophy. It will be critical to clarify
the role of microbiome/virome changes and infections in the
period preceding the development of CD and to find markers
(epigenetic changes, genetic expression, metabolome alterations,
T-cell markers) that predict the development of the disease at
the earliest stage possible. Related to this, it will be equally
important to identify the factors controlling evolution from CD
autoimmunity to mucosal damage and the biomarkers predictive
of such evolution to enable the identification of preventive
measures and non-dietary treatments. Finally, despite increased
awareness of CD, diagnostic delays are still common and the
appropriate policy to be implemented to improve the diagnostic
rate needs to be determined.
Analytical Aspects of Gluten
For reasons of better handling and long-term stability compared
to flours as evidenced by the excellent properties of PWG-gliadin
since its production almost 20 years ago, we continue to support
the use of isolates as reference materials. Because PWG-gliadin
only constitutes the alcohol-soluble fraction of wheat gluten, we
aim to provide prolamin and total gluten isolates from wheat, rye
and barley flours, respectively. The first steps will be to establish
a suitable protocol to extract all relevant immunoreactive gluten
proteins from the flours, characterize the exact composition of
the isolates and ensure homogeneity and solubility. Research
efforts to identify representative rye and barley cultivars have
just started as well as fundamental studies on suitable extraction
protocols. We recommend using the same reference material for
calibration of analytical methods for better comparability and
reproducibility of results.
The PWG acknowledges that more than one ELISA method
for the analysis of gluten in foods are currently used and that the
results of these methods are not comparable. The group does not
support the policy of the Codex Alimentarius to allow approval
of more than one type 1 method, because this is in disagreement
to the definition of a type 1 method. The Codex Alimentarius
should decide soon how to proceed, because several methods
are currently already available that fulfill all performance criteria
such as the R5, G12, and Total Gluten ELISAs. The PWG suggests
that performance data of these ELISAs obtained with identical
or at least comparable matrices should be compared. If existing
data is not sufficient, comparative studies need to be carried
out on the set of foods suggested in this paper. This could
result in a kind of guidebook suggesting specific ELISAs for
specific foods.
AUTHOR CONTRIBUTIONS
KS, CC, CG, KL, MS, RT, and PK wrote the first draft of the
manuscript. FC, CF, FK, DS, and OT contributed to revising
and editing the manuscript. All authors read and approved the
final manuscript.
Frontiers in Nutrition | www.frontiersin.org 9 March 2020 | Volume 7 | Article 29
Scherf et al. Prolamin Working Group
FUNDING
Open Access publication of this paper was funded by
Arbeitsgemeinschaft Getreideforschung e.V. (Association of
Cereal Research), Detmold, Germany.
ACKNOWLEDGMENTS
The PWG was grateful to all regular attendees of the annual
meetings for their active contributions as presenters as well as
during the discussions.
REFERENCES
1. Ludvigsson JF, Leffler DA, Bai JA, Biagi F, Fasano A, Green PHR, et al.
The Oslo definitions for coeliac disease and related terms. Gut. (2013)
62:43–52. doi: 10.1136/gutjnl-2011-301346
2. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al.
Identification of tissue transglutaminase as the autoantigen of celiac disease.
Nat Med. (1997) 3:797–801. doi: 10.1038/nm0797-797
3. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, Madsen
L, et al. Tissue transglutaminase selectively modifies gliadin peptides that
are recognized by gut-derived T cells in celiac disease. Nat Med. (1998)
4:713–7. doi: 10.1038/nm0698-713
4. Van de Wal Y, Kooy YMC, van Veelen PA, Pena SA, Mearin LM, Molberg
∅, et al. Small intestinal T cells of celiac disease patients recognize a natural
pepsin fragment of gliadin. Proc Natl Acad Sci USA. (1998) 95:1050–1054.
doi: 10.1073/pnas.95.17.10050
5. Fasano A. Celiac disease – how to handle a clinical chameleon. N Engl J Med.
(2003) 348:2568–70. doi: 10.1056/NEJMe030050
6. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, et al.
Prevalence of celiac cisease in at-risk and not-at-risk groups in the
United States: A large multicenter study. Arch Intern. Med. (2003) 163:286–
292. doi: 10.1001/archinte.163.3.286
7. Kahaly GJ, Frommer L, Schuppan D. Celiac disease and endocrine
autoimmunity – the genetic link. Autoimmun Rev. (2018) 17:1169–
75. doi: 10.1016/j.autrev.2018.05.013
8. Lundin KE, Sollid LM. Advances in coeliac disease. Curr Opin Gastroenterol.
(2014) 30:154–62. doi: 10.1097/MOG.0000000000000041
9. Schuppan D, Junker Y, Barisani D. Celiac disease: from
pathogenesis to novel therapies. Gastroenterology. (2009)
137:1912–33. doi: 10.1053/j.gastro.2009.09.008
10. Peräaho M, Kaukinen K, Mustalahti K, Vuolteenaho N, Mäki M, Laippala P,
et al. Effect of an oats-containing gluten-free diet on symptoms and quality
of life in coeliac disease. A randomized study Scand J Gastroenterol. (2004)
39:27–31. doi: 10.1080/00365520310007783
11. Srinivasan U, Leonard N, Jones E, Kasarda DD, Weir DG, O’Farrelly C,
et al. Absence of oats toxicity in adult coeliac disease. BMJ. (1996) 313:1300–
1. doi: 10.1136/bmj.313.7068.1300
12. Srinivasan U, Jones E, Carolan J, Feighery C. Immunohistochemical analysis
of coeliac mucosa following ingestion of oats. Clin Exp Immunol. (2006)
144:197–203. doi: 10.1111/j.1365-2249.2006.03052.x
13. Catassi C, Fabiani E, Iacono G, D’Agate C, Francavilla R, Biagi F, et al. A
prospective, double-blind, placebo-controlled trial to establish a safe gluten
threshold for patients with celiac disease. Am J Clin Nutr. (2007) 85:160–
6. doi: 10.1093/ajcn/85.1.160
14. Gianfrani C, Maglio M, Rotondi Aufiero V, Camarca A, Vocca I, Iaquinto G,
et al. Immunogenicity of monococcum wheat in celiac patients. Am J Clin
Nutr. (2012) 96:1339–45. doi: 10.3945/ajcn.112.040485
15. Gianfrani C, Camarca A, Mazzarella G, Di Stasio L, Rotondi Aufiero
V, Giardullo N, et al. Extensive in vitro gastrointestinal digestion
markedly reduces the immune-toxicity of Triticum monococcum wheat:
implication for celiac disease. Mol Nutr Food Res. (2015) 59:1844–
54. doi: 10.1002/mnfr.201500126
16. Bondar C, Araya RE, Guzman L, Rua EC, Chopita N, Chirdo
FG. Role of CXCR3/CXCL10 axis in immune cell recruitment
into the small intestine in celiac disease. PLoS ONE. (2014)
9:e89068. doi: 10.1371/journal.pone.0089068
17. García E, Llorente M, Hernando A, Kieffer R, Wieser H, Méndez E.
Development of a general procedure for complete extraction of gliadins
for heat processed and unheated foods. Eur J Gastroenterol Hepatol. (2005)
17:529–39. doi: 10.1097/00042737-200505000-00010
18. Don C, Halbmayr-Jech E, Rogers A, Koehler P. AACCI approved
methods technical committee report: collaborative study on the
immunochemical quantitation of intact gluten in rice flour and rice-
based products using G12 sandwich ELISA. Cereal Foods World. (2014)
59:187–93. doi: 10.1094/CFW-59-4-0605
19. Koehler P, Schwalb T, Immer U, Lacorn M, Wehling P, Don C. AACCI
approved methods technical committee report: collaborative study on the
immunochemical determination of intact gluten using an R5 sandwich
ELISA. Cereal Foods World. (2013) 58:36–40. doi: 10.1094/CFW-58-1-0036
20. Koehler P, Schwalb T, Immer U, Lacorn M, Wehling P, Don C.
AACCI approved methods technical committee report: collaborative study
on the immunochemical determination of partially hydrolyzed gluten
using an R5 competitive ELISA. Cereal Foods World. (2013) 58:154–
8. doi: 10.1094/CFW-58-3-0402
21. Lacorn M, Weiss T, Wehling P, Arlinghaus M, Scherf K. Quantification
of wheat, rye, and barley gluten in oat and oats products by ELISA
RIDASCREEN R© Total Gluten: Collaborative study, First Action 2018.15. J.
AOAC Int. (2019) 102:1535–43. doi: 10.5740/jaoacint.19-0094
22. Van Eckert R, Berghofer E, Ciclitira PJ, Chirdo F, Denery-
Papini S, Ellis HJ, et al. Towards a new gliadin reference
material - isolation and characterisation. J Cereal Sci. (2006)
43:331–41. doi: 10.1016/j.jcs.2005.12.009
23. Abadie V, Sollid LM, Barreiro LB, Jabri B. Integration of
genetic and immunological insights into a model of celiac
disease pathogenesis. Annu Rev Immunol. (2011) 29:493–
525. doi: 10.1146/annurev-immunol-040210-092915
24. Ludvigsson JF, Murray JA. Epidemiology of celiac disease. Gastroenterol Clin
North Am. (2019) 48:1–18. doi: 10.1016/j.gtc.2018.09.004
25. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al.
Global prevalence of celiac disease: systematic review andmeta-analysis.Clin
Gastroenterol Hepatol. (2018) 16:823–36.e2. doi: 10.1016/j.cgh.2017.06.037
26. Gatti S, Lionetti E, Balanzoni L, Verma AK, Galeazzi T, Gesuita R, et al.
Increased prevalence of celiac disease in school-age children in Italy. Clin
Gastroenterol Hepatol. (2019) 18:596–603. doi: 10.1016/j.cgh.2019.06.013
27. Ivarsson A, Myléus A, Norström F, van der Pals M, Rosén A, Högberg L,
et al. Prevalence of childhood celiac disease and changes in infant feeding.
Pediatrics. (2013) 131:e687–94. doi: 10.1542/peds.2012-1015
28. Ramakrishna BS, Makharia GK, Chetri K, Dutta S, Mathur P, Ahuja V,
et al. Prevalence of adult celiac disease in India: regional variations and
associations.Am JGastroenterol. (2016) 111:115–23. doi: 10.1038/ajg.2015.39
29. Kivelä L, Kaukinen K, Huhtala H, Lähdeaho ML, Mäki M, Kurppa K. At-risk
screened children with celiac disease are comparable in disease severity and
dietary adherence to those found because of clinical suspicion: a large cohort
study. J Peds. (2017) 183:115–21.e2. doi: 10.1016/j.jpeds.2016.12.077
30. Catassi C, Lionetti E. Case finding for celiac disease is ok,
but is it enough? J Pediatr Gastroenterol Nutr. (2013) 57:415–
7. doi: 10.1097/MPG.0b013e3182a45676
31. Hujoel IA, Van Dyke CT, Brantner T, Larson J, King KS, Sharma A, et al.
Natural history and clinical detection of undiagnosed coeliac disease in
a North American community. Aliment Pharmacol Ther. (2018) 47:1358–
66. doi: 10.1111/apt.14625
32. Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, and Erdtmann
F, et al. Increased prevalence and mortality in undiagnosed celiac disease.
Gastroenterology. (2009) 137:88–93. doi: 10.1053/j.gastro.2009.03.059
33. Catassi C, Kryszak D, Bhatti B, Sturgeon C, Helzlsouer K, Clipp SL,
et al. Natural history of celiac disease autoimmunity in a USA cohort
followed since 1974.AnnMed. (2010) 42:530–8. doi: 10.3109/07853890.2010.
514285
34. Grode L, Bech BH, Jensen TM, Humaidan P, Agerholm IE,
Plana-Ripoll O, et al. Prevalence, incidence, and autoimmune
Frontiers in Nutrition | www.frontiersin.org 10 March 2020 | Volume 7 | Article 29
Scherf et al. Prolamin Working Group
comorbidities of celiac disease: a nation-wide, population-based study
in Denmark from 1977 to 2016. Eur J Gastroeneterol Hepatol. (2018)
30:83–91. doi: 10.1097/MEG.0000000000000992
35. Lionetti E, Castellaneta S, Francavilla R, Pulvirenti A, Tonutti E, Amarri
S, et al. Introduction of gluten, HLA status, and the risk of celiac disease
in children. N Engl J Med. (2014) 371:1295–303. doi: 10.1056/NEJMoa14
00697
36. Vriezinga SL, Auricchio R, Bravi E, Castillejo G, Chmielewska A,
Crespo Escobar P, et al. Randomized feeding intervention in infants
at high risk for celiac disease. N Engl J Med. (2014) 371:1304–
15. doi: 10.1056/NEJMoa1404172
37. Aronsson CA, Lee HS, Liu E, Uusitalo U, Hummel S, Yang J, et al. Age at
gluten introduction and risk of celiac disease. Pediatrics. (2015) 135:239–
45. doi: 10.1542/peds.2014-1787
38. Størdal K, White RA, Eggesbø M. Early feeding and risk of celiac
disease in a prospective birth cohort. Pediatrics. (2013) 132:e1202–
1209. doi: 10.1542/peds.2013-1752
39. Aronsson CA, Lee HS, Hård af Segerstad EM, Uusitalo U, Yang J, Koletzko
S, et al. Association of gluten intake duuring the first 5 years of life with
incidence of celiac disease autoimmunity and celiac disease among children
at increased risk. JAMA. (2019) 322:514–23. doi: 10.1001/jama.2019.10329
40. Crespo-Escobar P, Mearin ML, Hervás D, Auricchio R, Castillejo G, Gyimesi
J, et al. The role of gluten consumption at an early age in celiac disease
development: a further analysis of the prospective PreventCD cohort study.
Am J Clin Nutr. (2017) 105:890–6. doi: 10.3945/ajcn.116.144352
41. Leonard MM, Fasano A. Gluten and celiac disease risk: Is it just a matter of
quantity? JAMA. (2019) 322:510–1. doi: 10.1001/jama.2019.9678
42. Lund-Blix NA, Mårild K, Tapia G, Norris JM, Stene LC, Størdal
K. Gluten intake in early childhood and risk of celiac disease in
childhood: a nationwide cohort study. Am J Gastroenterol. (2019) 114:1299–
306. doi: 10.14309/ajg.0000000000000331
43. Dydensborg Sander S, Hansen AV, Størdal K, Andersen AN, Murray JA,
Husby S. Mode of delivery is not associated with celiac disease. Clin
Epidemiol. (2018) 10:323–32. doi: 10.2147/CLEP.S152168
44. Dydensborg Sander S, Nybo Andersen AM, Murray JA, Karlstad
Ø, Husby S, Størdal K. Association between antibiotics in the first
year of life and celiac disease. Gastroenterology. (2019) 156:2217–
29. doi: 10.1053/j.gastro.2019.02.039
45. Kołodziej M, Patro-Gołab B, Gieruszczak-Białek D, Skórka A, Piescik-Lech
M, Baron R, et al. Association between early life (prenatal and postnatal)
antibiotic administration and coeliac disease: a systematic review. Arch Dis
Child. (2019) 104:1083–89. doi: 10.1136/archdischild-2019-317174
46. Kemppainen KM, Vehik K, Lynch KF, Larsson HE, Canepa RJ, Simell
V, et al. Association between early-life antibiotic use and the risk of
islet or celiac disease autoimmunity. JAMA Pediatr. (2017) 171:1217–
55. doi: 10.1001/jamapediatrics.2017.2905
47. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, et al.
Rotavirus infection frequency and risk of celiac disease autoimmunity in
early childhood: a longitudinal study. Am J Gastroenterol. (2006) 101:2333–
40. doi: 10.1111/j.1572-0241.2006.00741.x
48. Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T,
et al. Factors that increase risk of celiac disease autoimmunity after a
gastrointestinal infection in early life. Clin Gastroenterol Hepatol. (2017)
15:694–702.e5. doi: 10.1016/j.cgh.2016.10.033
49. Bouziat R, Biering SB, Kouame E, Sangani KA, Kang S, Ernest
JD, et al. Murine norovirus infection induces TH1 inflammatory
responses to dietary antigens. Cell Host Microbe. (2018)
24:677–88.e5. doi: 10.1016/j.chom.2018.10.004
50. Bouziat R, Hinterleitner R, Brown JJ, Stencel-Baerenwald JE, Ikizler M,
Mayassi T, et al. Reovirus infection triggers inflammatory responses to
dietary antigens and development of celiac disease. Science. (2017) 356:44–
50. doi: 10.1126/science.aah5298
51. Kahrs CR, Chuda K, Tapia G, Stene LC, Mårild K, Rasmussen T, et al.
Enterovirus as trigger of coeliac disease: nested case-control study within
prospective birth cohort. BMJ. (2019) 364:l231. doi: 10.1136/bmj.l231
52. Auricchio R, Cielo D, de Falco R, Galatola M, Bruno V, Malamisura B,
et al. Respiratory infections and the risk of celiac disease. Pediatrics. (2017)
140:e20164102. doi: 10.1542/peds.2016-4102
53. Pozo-Rubio T, Olivares M, Nova E, De Palma G, Mujico JR, Ferrer MD, et al.
Immune development and intestinal microbiota in celiac disease. Clin Dev
Immunol. (2012) 2012:654143. doi: 10.1155/2012/654143
54. Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga ML, Sanz Y.
Duodenal-mucosal bacteria associated with celiac disease in children. Appl
Environ Microbiol. (2013) 79:5472–9. doi: 10.1128/AEM.00869-13
55. Olivares M, Walker AW, Capilla A, Benítez-Páez A, Palau F, Parkhill J, et al.
Gut microbiota trajectory in early life may predict development of celiac
disease.Microbiome. (2018) 6:36. doi: 10.1186/s40168-018-0415-6
56. Rintala A, Riikonen I, Toivonen A, Pietilä S, Munukka E, Pursiheimo JP,
et al. Early fecal microbiota composition in children who later develop
celiac disease and associated autoimmunity. Scand J Gastroenterol. (2018)
53:403–9. doi: 10.1080/00365521.2018.1444788
57. Caminero A, Galipeau HJ, McCarville JL, Johnston CW, Bernier SP,
Russell AK, et al. Duodenal bacteria from patients with celiac disease and
healthy subjects distinctly affect gluten breakdown and immunogenicity.
Gastroenterology. (2016) 151:670–83. doi: 10.1053/j.gastro.2016.06.041
58. Caminero A, McCarville JL, Galipeau HJ, Deraison C, Bernier SP, Constante
M, et al. Duodenal bacterial proteolytic activity determines sensitivity to
dietary antigen through protease-activated receptor-2. Nat Commun. (2019)
10:1198. doi: 10.1038/s41467-019-09037-9
59. Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P,
Partanen J, et al. Diagnosing mild enteropathy celiac disease: a
randomized, controlled clinical study. Gastroenterology. (2009)
136:816–23. doi: 10.1053/j.gastro.2008.11.040
60. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T,
et al. Prevalence of celiac disease among children in Finland. N Engl J Med.
(2003) 348:2517–24. doi: 10.1056/NEJMoa021687
61. Salmi TT, Hervonen K, Kurppa K, Collin P, Kaukinen K, Reunala T.
Celiac disease evolving into dermatitis herpetiformis in patients adhering
to normal or gluten-free diet. Scand J Gastroenterol. (2015) 50:387–
92. doi: 10.3109/00365521.2014.974204
62. Auricchio R, Mandile R, Del Vecchio MR, Scapaticci S, Galatola M, Maglio
M, et al. Progression of celiac disease in children with antibodies against
tissue transglutaminase and normal duodenal architecture.Gastroenterology.
(2019) 157:413–20. doi: 10.1053/j.gastro.2019.04.004
63. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E, et al. Evidence
for a primary association of celiac disease to a particular HLA-DQ alpha/beta
heterodimer. J Exp Med. (1989) 169:345–50. doi: 10.1084/jem.169.1.345
64. Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, et al.
Gliadin-specific, HLA-DQ(alpha 1∗0501, beta 1∗0201) restricted T cells
isolated from the small intestinal mucosa of celiac disease patients. J Exp
Med. (1993) 178:187–96. doi: 10.1084/jem.178.1.187
65. Lundin KE, Scott H, Fausa O, Thorsby E, Sollid LM. T cells from the
small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient
preferentially recognize gliadin when presented by DQ8. Hum Immunol.
(1994) 41:285–91. doi: 10.1016/0198-8859(94)90047-7
66. Bodd M, Kim CY, Lundin KE, Sollid LM. T-cell response to
gluten in patients with HLA-DQ2.2 reveals requirement of
peptide-MHC stability in celiac disease. Gastroenterology. (2012)
142:552–61. doi: 10.1053/j.gastro.2011.11.021
67. Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, et al.
The HLA-DQ2 gene dose effect in celiac disease is directly related to the
magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad
Sci USA. (2003) 100:12390–5. doi: 10.1073/pnas.2135229100
68. Pisapia L, Camarca A, Picascia S, Bassi V, Barba P, Del Pozzo G, et al. HLA-
DQ2.5 genes associated with celiac disease risk are preferentially expressed
with respect to non-predisposing HLA genes: Implication for anti-gluten T
cell response. J Autoimmun. (2016) 70:63–72. doi: 10.1016/j.jaut.2016.03.016
69. Gianfrani C, Pisapia L, Picascia S, Strazzullo M, Del Pozzo G. Expression
level of risk genes of MHC class II is a susceptibility factor for autoimmunity:
new insights. J Autoimmun. (2018) 89:1–10. doi: 10.1016/j.jaut.2017.12.016
70. Farina F, Picascia S, Pisapia L, Barba P, Vitale S, Franzese A, et al. HLA-
DQA1 and HLA-DQB1 alleles, conferring susceptibility to celiac disease and
type 1 diabetes, are more expressed than non-predisposing alleles and are
coordinately regulated. Cells. (2019) 8:E751. doi: 10.3390/cells8070751
71. Arentz-Hansen H, McAdam SN, Molberg O, Fleckenstein B, Lundin KEA,
Jørgensen TJD, et al. Celiac lesion T cells recognize epitopes that cluster
Frontiers in Nutrition | www.frontiersin.org 11 March 2020 | Volume 7 | Article 29
Scherf et al. Prolamin Working Group
in regions of gliadins rich in proline residues. Gastroenterology. (2002)
123:803–9. doi: 10.1053/gast.2002.35381
72. Van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopoulos G,
et al. Selective deamidation by tissue transglutaminase strongly enhances
gliadin-specific T cell reactivity. J Immunol. (1998) 161:1585–8.
73. Petersen J, Montserrat V, Mujico JR, Loh KL, Beringer DX, van Lummel
M, et al. T-cell receptor recognition of HLA-DQ2–gliadin complexes
associated with celiac disease. Nat Struct Mol Biol. (2014) 21:480–
8. doi: 10.1038/nsmb.2817
74. Petersen J, Kooy-Winkelaar Y, Loh KL, TranM, van Berrgen J, Koning F, et al.
Diverse T cell receptor gene usage in HLA-DQ8-associated celiac disease
converges into a consensus binding solution. Structure. (2016) 24:1643–
57. doi: 10.1016/j.str.2016.07.010
75. Sollid LM, Qiao SW, Anderson RP, Gianfrani C, Koning F.
Nomenclature and listing of celiac disease relevant gluten T-cell
epitopes restricted by HLA-DQ molecules. Immunogenetics. (2012)
64:455–60. doi: 10.1007/s00251-012-0599-z
76. Quarsten H, McAdam SN, Jensen T, Arentz-Hansen H, Molberg
O, Lundin KEA, et al. Staining of celiac disease-relevant T
cells by peptide-DQ2 multimers. J Immunol. (2001) 167:4861–
8. doi: 10.4049/jimmunol.167.9.4861
77. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS. In vivo antigen
challenge in celiac disease identifies a single transglutaminase-modified
peptide as the dominant A-gliadin T-cell epitope. Nat Med. (2000) 6:337–
42. doi: 10.1038/73200
78. Anderson RP, van Heel DA, Tye-Din JA, Barnardo M, Salio M, Jewell DP,
et al. T cells in peripheral blood after gluten challenge in coeliac disease. Gut.
(2005) 54:1217–723. doi: 10.1136/gut.2004.059998
79. Raki M, Fallang LE, Brottveit M, Bergseng E, Quarsten H, Lundin KEA,
et al. Tetramer visualization of gut-homing gluten-specific T cells in the
peripheral blood of celiac disease patients. Proc Natl Acad Sci USA. (2007)
104:2831–6. doi: 10.1073/pnas.0608610104
80. Brottveit M, Raki M, Bergseng E, Fallang L-E, Simonsen B, Lovik A, et al.
Assessing possible celiac disease by an HLA-DQ2-gliadin tetramer test. Am J
Gastroenterol. (2011) 106:1318–24. doi: 10.1038/ajg.2011.23
81. Sarna VK, Lundin KEA, Morkrid L, Qiao S-W, Sollid LM, Christophersen
A, et al. HLA-DQ-Gluten tetramer blood test accurately identifies patients
with and without celiac disease in absence of gluten consumption.
Gastroenterology. (2018) 154:886–96.e6. doi: 10.1053/j.gastro.2017.11.006
82. Christophersen A, Raki M, Bergseng E, Lundin KEA, Jahnsen J, Sollid LM,
et al. Tetramer-visualized gluten-specific CD4+T cells in blood as a potential
diagnostic marker for coeliac disease without oral gluten challenge. U Eur
Gastroenterol J. (2014) 2:268–78. doi: 10.1177/2050640614540154
83. Sarna VK, Skodje GI, Reims HM, Risnes LF, Dahal-Koirala S, Sollid LM,
et al. HLA-DQ:gluten tetramer test in blood gives better detection of coeliac
patients than biopsy after 14-day gluten challenge. Gut. (2018) 67:1606–13.
doi: 10.1136/gutjnl-2017-314461
84. Christophersen A, Lund EG, Snir O, Solà E, Kanduri C, Dahal-Koirala
S, et al. Distinct phenotype of CD4+ T cells driving celiac disease
identified in multiple autoimmune conditions. Nat Med. (2019) 25:734–
7. doi: 10.1038/s41591-019-0403-9
85. Zühlke S, Fremgaard Risnes L, Dahal-Koirala S, Christophersen A, Sollid
LM, Lundin KEA. CD38 expression on gluten-specific T cells is a robust
marker of gluten re-exposure in coeliac disease. U Eur Gastroent J. (2019)
7:1337–44. doi: 10.1177/2050640619874183
86. Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al.
European Society for the Study of Coeliac Disease (ESsCD) guideline for
coeliac disease and other gluten-related disorders. United Eur Gastroenterol
J. (2019) 7:583–613. doi: 10.1177/2050640619844125
87. Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, et al.
Cytokine release and gastrointestinal symptoms after gluten challenge in
celiac disease. Sci Adv. (2019) 5:eaaw7756. doi: 10.1126/sciadv.aaw7756
88. Tye-Din JA, Skodje GI, Sarna VK, Dzuris JL, Russell AK, Goel G, et al.
Cytokine release after gluten ingestion differentiates coeliac disease from
self-reported gluten sensitivity. United Eur. Gastroenterol. J. (2019) 8:108–
18. doi: 10.1177/2050640619874173
89. Penagini F, Dilillo D, Meneghin F, Mameli C, Fabiano V, Zuccotti GV.
Gluten-free diet in children: an approach to a nutritionally adequate and
balanced diet. Nutrients. (2013) 5:4553–65. doi: 10.3390/nu5114553
90. Leffler DA, Dennis M, Edwards George JB, Jamma S, Magge S, Cook
EF, et al. A simple validated gluten-free diet adherence survey for
adults with celiac disease. Clin Gastroenterol Hepatol. (2009) 7:530–
6. doi: 10.1016/j.cgh.2008.12.032
91. Troncone R, Mayer M, Spagnuolo F, Maiuri L, Greco L. Endomysial
antibodies as unreliable markers for slight dietary transgressions in
adolescents with celiac disease. J Pediatr Gastroenterol Nutr. (1995) 21:69–
72. doi: 10.1097/00005176-199507000-00012
92. Comino I, Fernández-Bañares F, Esteve M, Ortigosa L, Castillejo G,
Fambuena B, et al. Fecal gluten peptides reveal limitations of serological
tests and food questionnaires for monitoring gluten-free diet in celiac disease
patients. Am J Gastroenterol. (2016) 111:1456–65. doi: 10.1038/ajg.2016.439
93. Keck B, Köhler P, Wieser H. Disulphide bonds in wheat gluten:
cystine peptides derived from gluten proteins following peptic
and thermolytic digestion. Z Lebensm Unters Forsch. (1995)
200:432–9. doi: 10.1007/BF01193253
94. Wieser H. Chemistry of gluten proteins. Food Microbiol. (2007) 24:115–
9. doi: 10.1016/j.fm.2006.07.004
95. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural
basis for gluten intolerance in celiac sprue. Science. (2002) 297:2275–
9. doi: 10.1126/science.1074129
96. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S,
Candalh C, et al. Secretory IgA mediates retrotranscytosis of intact gliadin
peptides via the transferrin receptor in celiac disease. J Exp Med. (2008)
205:143–54. doi: 10.1084/jem.20071204
97. Gianfrani C, Auricchio S, Troncone R. Adaptive and innate
immune responses in coeliac disease. Immunol Lett. (2005)
99:141–5. doi: 10.1016/j.imlet.2005.02.017
98. Sollid LM, Tye-Din JA, Qiao SW, Anderson RP, Gianfrani C, Koning F.
Update 2020: nomenclature and listing of celiac disease–relevant gluten
epitopes recognized by CD4+ T cells. Immunogenetics. (2020) 72:85–
8. doi: 10.1007/s00251-019-01141-w
99. Junker Y, Zeissig S, Kim SJ, Barisani D, Wieser H, Leffler DA, et al. Wheat
amylase trypsin inhibitors drive intestinal inflammation via activation of toll-
like receptor 4. J Exp Med. (2012) 209:2395–408. doi: 10.1084/jem.20102660
100. Brouns F, van Rooy G, Shewry P, Rustgi S, Jonkers D. Adverse reactions
to wheat or wheat components. Compr Rev Food Sci Food Saf. (2019)
18:1437–52. doi: 10.1111/1541-4337.12475
101. Rustgi S, Shewry P, Brouns F, Deleu LJ, Delcour JA. Wheat seed proteins:
factors influencing their content, composition, and technological properties,
and strategies to reduce adverse reactions. Compr Rev Food Sci Food Saf.
(2019) 18:1751–69. doi: 10.1111/1541-4337.12493
102. Sollid LM, Lundin KEA. Diagnosis and treatment of celiac disease. Mucosal
Immunology. (2009) 2:3–7. doi: 10.1038/mi.2008.74
103. Tye-Din JA, Galipeau HJ, Agardh D. Celiac disease: a review of current
concepts in pathogenesis, prevention, and novel therapies. Front Pediatr.
(2018) 6:350. doi: 10.3389/fped.2018.00350
104. Cavaletti L, Taravella A, Carrano L, Carenzi G, Sigurta G, Solinas
N, et al. E40, a novel microbial protease efficiently detoxifying gluten
proteins, for the dietary management of gluten intolerance. Sci Rep. (2019)
9:13147. doi: 10.1038/s41598-019-48299-7
105. Gass J, Bethune MT, Siegel M, Spencer A, Khosla C. Combination
enzyme therapy for gastric digestion of dietary gluten in patients with
celiac sprue.Gastroenterology. (2007) 133:472–80. doi: 10.1053/j.gastro.2007.
05.028
106. Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, Koning
F. Efficient degradation of gluten by a prolyl endoprotease in a
gastrointestinal model: Implications for coeliac disease. Gut. (2008) 57:25–
32. doi: 10.1136/gut.2006.111609
107. Wolf C, Siegel JB, Tinberg C, Camarca A, Gianfrani C, Paski S, et al.
Engineering of Kuma030: A gliadin peptidase that rapidly degrades
immunogenic gliadin peptides in gastric conditions. J Am Chem Soc. (2015)
137:13106–13. doi: 10.1021/jacs.5b08325
108. Bethune MT, Khosla C. Oral enzyme therapy for celiac sprue. Methods
Enzymol. (2012) 502:241–71. doi: 10.1016/B978-0-12-416039-2.00013-6
109. König J, Holster S, Bruins MJ, Brummer RJ. Randomized
clinical trial: effective gluten degradation by Aspergillus niger-
derived enzyme in a complex meal setting. Sci Rep. (2017)
7:13100. doi: 10.1038/s41598-017-13587-7
Frontiers in Nutrition | www.frontiersin.org 12 March 2020 | Volume 7 | Article 29
Scherf et al. Prolamin Working Group
110. Knorr V, Wieser H, Koehler P. Production of gluten-free
beer by peptidase treatment. Eur Food Res Technol. (2016)
242:1129–40. doi: 10.1007/s00217-015-2617-5
111. Osorio CE, Wen N, Mejías JH, Liu B, Reinbothe S, von Wettstein
D, et al. Development of wheat genotypes expressing a glutamine-
specific endoprotease from barley and a prolyl endopeptidase
from Flavobacterium meningosepticum or Pyrococcus furiosus as a
potential remedy to celiac disease. Funct Integr Genomics. (2019)
19:123–36. doi: 10.1007/s10142-018-0632-x
112. Osorio CE, Wen N, Mejías JH, Mitchell S, von Wettstein D, Rustgi
S. Directed-mutagenesis of Flavobacterium meningosepticum prolyl-
oligopeptidase and a glutamine-specific endopeptidase from barley. Front
Nutr. (2020) 7:11. doi: 10.3389/fnut.2020.00011
113. Dennis M, Lee AR, McCarthy T. Nutritional considerations
of the gluten-free diet. Gastroenterol Clin North Am. (2019)
48:53–72. doi: 10.1016/j.gtc.2018.09.002
114. Rabinowitz LG, Zylberberg HM, Levinovitz A, Stockwell MS, Green PHR,
Lebwohl B. Skepticism regarding vaccine and gluten-free food safety among
patients with celiac disease and non-celiac gluten sensitivity. Dig Dis Sci.
(2018) 63:1158–64. doi: 10.1007/s10620-017-4879-1
115. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med. (2011)
269:604–13. doi: 10.1111/j.1365-2796.2011.02376.x
116. Kurppa K, Hietikko M, Sulic A-M, Kaukinen K, Lindfors K. Current status
of drugs in development for celiac disease. Expert Opin Invest Drugs. (2014)
23:1079–91. doi: 10.1517/13543784.2014.916274
117. Lindfors K, Ciacci C, Kurppa K, Lundin KEA, Makharia GK,
Mearin ML, et al. Coeliac disease. Nat Rev Dis Primers. (2019)
5:3. doi: 10.1038/s41572-018-0054-z
118. Serena G, Kelly CP, Fasano A. Nondietary therapies for
celiac disease. Gastroenterol Clin North Am. (2019) 48:145–
63. doi: 10.1016/j.gtc.2018.09.011
119. Christophersen A, Risnes LF, Dahal-Koirala S, Sollid LM. Therapeutic and
diagnostic implications of T cell sarring in celiac disease and beyond. Trends
Mol Med. (2019) 25:836–52. doi: 10.1016/j.molmed.2019.05.009
120. Korneychuk N, Meresse B, Cerf-Bensussan N. Lessons from
rodent models in celiac disease. Mucosal Immunol. (2015)
8:18–28. doi: 10.1038/mi.2014.102
121. Freitag TL, Podojil JR, Pearson RM, Fokta FJ, Sahl C, Messing M, et al.
Gliadin nanoparticles induce immune tolerance to gliadin in mouse models
of celiac disease. Gastroenterology. (2020). doi: 10.1053/j.gastro.2020.01.045
122. Abadie V, Kim SM, Lejeune T, Palanski BA, Ernest JD, Tastet O, et al. IL-
15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. Nature.
(2020) 578:600–4. doi: 10.1038/s41586-020-2003-8
123. International Wheat Genome Sequencing Consortium (IWGSC), Appels R,
Eversole K, Stein N, Feuillet C, Keller B, et al. Shifting the limits in wheat
research and breeding using a fully annotated reference genome. Science.
(2018) 361:eaar7191. doi: 10.1126/science.aar7191
124. Juhasz A, Belova T, Florides CG, Maulis C, Fischer I, Gell G, et al. Genome
mapping of seed-borne allergens and immunoresponsive proteins in wheat.
Sci Adv. (2018) 4:eaar8602. doi: 10.1126/sciadv.aar8602
125. Kondrashova A, Mustalahti K, Kaukinen K, Viskari H, Volodicheva
V, Haapala AM, et al. Lower economic status and inferior hygienic
environment may protect against celiac disease. Ann Med. (2008) 40:223–
1. doi: 10.1080/07853890701678689
126. Unalp-Arida A, Ruhl CE, Choung RS, Brantner TL, Murray JA. Lower
prevalence of celiac disease and gluten-related disorders in persons living in
Southern vs Northern latitudes of the United States.Gastroenterology. (2017)
152:1922–32.e2. doi: 10.1053/j.gastro.2017.02.012
127. Kasarda DD. Can an increase in celiac disease be attributed to an increase in
the gluten content of wheat as a consequence of wheat breeding? J Agric Food
Chem. (2013) 61:1155–9. doi: 10.1021/jf305122s
128. Van den Broeck HC, De Jong HC, Salentijn EMJ, Dekking L, Bosch
D, Hamer RJ, et al. Presence of celiac disease epitopes in modern and
old hexaploid wheat varieties. Wheat breeding may have contributed to
increased prevalence of celiac disease. Theor Appl Genet. (2010) 121:1527–
39. doi: 10.1007/s00122-010-1408-4
129. Molberg O, Uhlen AK, Jensen T, Flaete NS, Fleckenstein B, Arentz-
Hansen H, et al. Mapping of gluten T-cell epitopes in bread wheat
ancestors: Implications for celiac disease. Gastroenterology. (2005) 128:393–
401. doi: 10.1053/j.gastro.2004.11.003
130. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, Drijfhout JW, Jonker
H, van Soest L, et al. Natural variation in toxicity of wheat: potential for
selection of nontoxic varieties for celiac disease patients. Gastroenterology.
(2005) 129:797–806. doi: 10.1053/j.gastro.2005.06.017
131. Van den Broeck H, Hongbing C, Lacaze X, Dusautoir JC, Gilissen L,
Smulders M, et al. In search of tetraploid wheat accessions reduced
in celiac disease-related gluten epitopes. Mol Biosyst. (2010) 6:2206–
13. doi: 10.1039/c0mb00046a
132. Geisslitz S, Wieser H, Scherf KA, Koehler P. Gluten protein composition
and aggregation properties as predictors for bread volume of common
wheat, spelt, durum wheat, emmer and einkorn. J Cereal Sci. (2018) 83:204–
12. doi: 10.1016/j.jcs.2018.08.012
133. Geisslitz S, Longin CFH, Scherf KA, Koehler P. Comparative study
on gluten protein composition of ancient (einkorn, emmer and spelt)
and modern wheat species (durum and common wheat). Foods. (2019)
8:409. doi: 10.3390/foods8090409
134. Ozuna CV, Barro F. Characterization of gluten proteins and celiac disease-
related immunogenic epitopes in the Triticeae: cereal domestication and
breeding contributed to decrease the content of gliadins and gluten. Mol
Breed. (2018) 38:22. doi: 10.1007/s11032-018-0779-0
135. Boukid F, Prandi B, Sforza S, Sayar R, Seo YW,Mejri M, et al. Understanding
the effects of genotype, growing year, and breeding on Tunisian durum
wheat allergenicity. 2. The celiac disease case. J Agric Food Chem. (2017)
65:5837–46. doi: 10.1021/acs.jafc.7b02041
136. Malalgoda M, Meinhardt SW, Simsek S. Detection and quantitation
of immunogenic epitopes related to celiac disease in historical and
modern hard red spring wheat cultivars. Food Chem. (2018) 264:101–
7. doi: 10.1016/j.foodchem.2018.04.131
137. Ribeiro M, Rodriguez-Quijano M, Nunes FM, Carrillo JM, Branlard G,
Igrejas G. New insights into wheat toxicity: breeding did not seem to
contribute to a prevalence of potential celiac disease’s immunostimulatory
epitopes. Food Chem. (2016) 213:8–18. doi: 10.1016/j.foodchem.2016.06.043
138. Schalk K, Lang C, Wieser H, Koehler P, Scherf KA. Quantitation of
the immunodominant 33-mer peptide from α-gliadin in wheat flours
by liquid chromatography tandem mass spectrometry. Sci Rep. (2017)
7:45092. doi: 10.1038/srep45092
139. Iacomino G, Di Stasio L, Fierro O, Picariello G, Venezia A, Gazza L,
et al. Protective effects of ID331 Triticum monococcum gliadin on in
vitro models of the intestinal epithelium. Food Chem. (2016) 212:537–
42. doi: 10.1016/j.foodchem.2016.06.014
140. Tanner GJ, Blundell MJ, Colgrave ML, Howitt CA. Creation of the first ultra-
low gluten barley (Hordeum vulgare L.) for coeliac and gluten-intolerant
populations. Plant Biotechnol J. (2016) 14:1139–50. doi: 10.1111/pbi.12482
141. Jouanin A, Gilissen LJWJ, Boyd LA, Cockram J, Leigh FJ,Wallington EJ, et al.
Food processing and breeding strategies for coeliac-safe and healthy wheat
products. Food Res Int. (2018) 110:11–21. doi: 10.1016/j.foodres.2017.04.025
142. Shewry PR, Tatham AS. Improving wheat to remove coeliac
epitopes but retain functionality. J Cereal Sci. (2016) 67:12–
21. doi: 10.1016/j.jcs.2015.06.005
143. García-Molina MD, Giménez MJ, Sánchez-León S, Barro F. Gluten free
wheat: are we there? Nutrients. (2019) 11:487. doi: 10.3390/nu11030487
144. Becker D, Wieser H, Koehler P, Folck A, Mühling K-H, Zörb C. Protein
composition and techno-functional properties of transgenic wheat with
reduced alpha-gliadin content obtained by RNA interference. J Appl Bot Food
Qual. (2012) 85:23–33.
145. Gil-Humanes J, Pistón F, Hernando A, Alvarez JB, Shewry PR, Barro F.
Silencing of γ-gliadins by RNA interference (RNAi) in bread wheat. J Cereal
Sci. (2008) 48:565–8. doi: 10.1016/j.jcs.2008.03.005
146. Altenbach SB, Tanaka CK, Bradford W, Seabourn BW. Silencing of omega-
5 gliadins in transgenic wheat eliminates a major source of environmental
variability and improves dough mixing properties of flour. BMC Plant Biol.
(2014) 14:1. doi: 10.1186/s12870-014-0393-1
147. Altenbach SB, Chang H-C, Yu XB, Seabourn BW, Green PH, Alaedini A.
Elimination of omega-1,2 gliadins from bread wheat (Triticum aestivum)
flour: effects on immunogenic potential and end-use quality. Front Plant Sci.
(2019) 10:580. doi: 10.3389/fpls.2019.00580
Frontiers in Nutrition | www.frontiersin.org 13 March 2020 | Volume 7 | Article 29
Scherf et al. Prolamin Working Group
148. Barro F, Iehisa JCM, Giménez MJ, García-Molina MD, Ozuna CV, Comino
I, et al. Targeting of prolamins by RNAi in bread wheat: effectiveness of
seven silencing-fragment combinations for obtaining lines devoid of coeliac
disease epitopes from highly immunogenic gliadins. Plant Biotechnol J.
(2016) 14:986–996. doi: 10.1111/pbi.12455
149. Sánchez-León S, Gil-Humanes J, Ozuna CV, Giménez MJ, Sousa C, Voytas
DF, et al. Low-gluten, non-transgenic wheat engineered with CRISPR/Cas9.
Plant Biotechnol J. (2018) 16:902–10. doi: 10.1111/pbi.12837
150. Jouanin A, Schaart JG, Boyd LA, Cockram J, Leigh FJ, Bates R, et al. Outlook
for coeliac disease patients: towards bread wheat with hypoimmunogenic
gluten by gene editing of α- and γ-gliadin gene families. BMC Plant Biol.
(2019) 19:333. doi: 10.1186/s12870-019-1889-5
151. Jouanin A, Boyd LA, Visser RGF, Smulders MJM. Development of wheat
with hypoimmunogenic gluten obstructed by the gene editing policy in
Europe. Front Plant Sci. (2018) 9:1523. doi: 10.3389/fpls.2018.01523
152. Skerritt JH, Hill AS. Monoclonal antibody sandwich enzyme immunoassays
for determination of gluten in foods. J Agric Food Chem. (1990) 38:1771–
8. doi: 10.1021/jf00098a029
153. Valdés I, García E, Llorente M, Méndez E. Innovative approach to low-
level gluten determination in foods using a novel sandwich enzyme-linked
immunosorbent assay protocol. Eur J Gastroenterol Hepatol. (2003) 15:465–
74. doi: 10.1097/01.meg.0000059119.41030.df
154. Morón B, Bethune MT, Comino I, Manyani H, Ferragud M, López MC, et al.
Toward the assessment of food toxicity for celiac patients: characterization of
monoclonal antibodies to a main immunogenic gluten peptide. PLoS ONE.
(2008) 3:e2294. doi: 10.1371/journal.pone.0002294
155. Mitea C, Kooy-Winkelaar Y, van Veelen P, de Ru A, Drijfhout JW,
Koning F, et al. Fine specificity of monoclonal antibodies against celiac
disease-inducing peptides in the gluteom. Am J Clin Nutr. (2008) 88:1057–
66. doi: 10.1093/ajcn/88.4.1057
156. Bugyi Z, Török K, Hajas L, Adonyi Z, Popping B, Tömösközi S.
Comparative study of commercially available gluten ELISA kits using an
incurred reference material. Qual Assur Saf Crops Foods. (2013) 5:79–
87. doi: 10.3920/QAS2012.0174
157. Rzychon M, Brohée M, Cordeiro F, Haraszi R, Ulberth F, O’Connor G. The
feasibility of harmonizing gluten ELISA measurements. Food Chem. (2017)
234:144–54. doi: 10.1016/j.foodchem.2017.04.092
158. Scherf KA. Gluten analysis of wheat starches with seven commercial ELISA
test kits - up to six different values. Food Anal Methods. (2017) 10:234–
46. doi: 10.1007/s12161-016-0573-8
159. Boison J, Allred L, Almy D, Anderson L, Baumert J, Bhandari S,
et al. Standard method performance requirements (SMPRs R©) 2017.021:
quantitation of wheat, rye, and barley gluten in oats. J AOAC Int. (2018)
101:1238–42. doi: 10.5740/jaoacint.SMPR2017.021
160. Wehling P, Scherf KA. Preparation of validation materials for estimating
gluten recovery by ELISA according to SMPR 2017.021. J AOAC Int. (2019)
103:1–6. doi: 10.5740/jaoacint.19-0081
161. Abbott M, Hayward S, Ross W, Godefroy SB, Ulberth F, Van Hengel AJ,
et al. Validation procedures for quantitative food allergen ELISA methods:
community guidance and best practices. J. AOAC Int. (2010) 93:442–50.
doi: 10.1093/jaoac/93.2.442
162. Diaz-Amigo C, Popping B. Accuracy of ELISA detection methods for gluten
and reference materials: a realistic assessment. J Agric Food Chem. (2013)
61:5681–8. doi: 10.1021/jf3046736
163. Scherf KA, Poms RE. Recent developments in analytical methods for tracing
gluten. J Cereal Sci. (2016) 67:112–22. doi: 10.1016/j.jcs.2015.08.006
164. Lexhaller B, Tompos C, Scherf KA. Fundamental study on
reactivities of gluten protein types from wheat, rye and
barley with five sandwich ELISA test kits. Food Chem. (2017)
237:320–30. doi: 10.1016/j.foodchem.2017.05.121
165. Schalk K, Lexhaller B, Koehler P, Scherf KA. Isolation and
characterization of gluten protein types from wheat, rye, barley
and oats for use as reference materials. PLoS ONE. (2017)
12:e0172819. doi: 10.1371/journal.pone.0172819
166. Hajas L, Scherf KA, Török K, Bugyi Z, Schall E, Poms RE, et al.
Variation in protein composition among wheat (Triticum aestivum L.)
cultivars to identify cultivars suitable as reference material for wheat gluten
analysis. Food Chem. (2018) 267:387–94. doi: 10.1016/j.foodchem.2017.
05.005
167. Schall E, Scherf KA, Bugyi Z, Hajas L, Török K, Koehler P, et al.
Characterisation and comparison of selected wheat (Triticum aestivum L.)
cultivars and their blends to develop a gluten reference material. Food Chem.
(2020) 313:126049. doi: 10.1016/j.foodchem.2019.126049
168. Bruins Slot ID, Bremer MGEG, van der Fels-Klerx I, Hamer RJ. Evaluating
the performance of gluten ELISA test kits: the numbers do not tell the tale.
Cereal Chem. (2015) 92:513–21. doi: 10.1094/CCHEM-07-14-0166-R
169. AOAC SMPR 2016.002. Standard Method Performance Requirements
(SMPRs R©) for Detection and Quantitation of Selected Food Allergens.
Rockville, MD: AOAC International (2006).
170. Koerner TB, Abbott M, Godefroy SB, Popping B, Yeung JM, Diaz-Amigo
C, et al. Validation procedures for quantitative gluten ELISA methods:
AOAC allergen community and best practices. J AOAC Int. (2013) 96:1033–
40. doi: 10.5740/jaoacint.13-043
171. AOACAppendix D.Guidelines for Collaborative Study Procedures to Validate
Characteristics of a Method of Analysis, Official Methods of Analysis. 20th ed.
Rockville, MD: AOAC International (2016). Available online at: http://www.
eoma.aoac.org/app_d.pdf (accessed December 11, 2019).
172. AOAC Appendix F. Guidelines for Standard Method Performance
Requirements, Official Methods of Analysis. 20th ed. Rockville, MD:
AOAC International (2016). Available online at: http://www.eoma.aoac.org/
app_f.pdf (accessed December 11, 2019).
173. Koehler P, Chirdo F, Mothes F, Tranquet O, Scherf KA. Considerations
concerning methods for gluten quantitation in foods (R5/G12 ELISA).
In: Koehler P, editor. Proceedings of the 30th Meeting, Working Group on
Prolamin Analysis and Toxicity. (Freising) (2017). p. 137–42.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Scherf, Catassi, Chirdo, Ciclitira, Feighery, Gianfrani, Koning,
Lundin, Schuppan, Smulders, Tranquet, Troncone and Koehler. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Nutrition | www.frontiersin.org 14 March 2020 | Volume 7 | Article 29
